ImmunityBio said ANKTIVA plus BCG met the trial's main goal in patients new to BCG treatment, supporting the treatment's case. The filing gives no measure of the benefit or news of approval, so broader use is not established.
Meeting the trial's main goal supports ANKTIVA plus BCG as a treatment for this type of bladder cancer. The filing gives no figures showing how well it worked, and reports no approval, so it does not show how widely the treatment may be used.
Follow ImmunityBio, Inc. (IBRX) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for IBRX